Global Monoamine Oxidase (MAO) Inhibitor Drugs Market, By Types (MAO-A Inhibitor, MAO-B Inhibitor), Drugs (Isocarboxazid, Phenelzine, Tranylcypromine, Others), Disorder Type (Parkinson’s Disease, Depression, Anxiety, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Analysis and Insights Global Monoamine Oxidase (MAO) Inhibitor Drugs Market
Monoamine oxidase (MAO) inhibitor drugs market size is projected to grow at a compound annual growth rate of 4.12% over the forecast period of 2022 to 2029. Data Bridge Market Research report on monoamine oxidase (MAO) inhibitor drugs market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the market’s growth.
Monoamine Oxidase (MAO) Inhibitors are the drugs that are basically utilized for treatment of depression. These drugs usually work by prevention of breakdown of the serotonin, dopamine, and norepinephrine in CNS and maintains their availability. They also possess huge risk of distributing other neurotransmitters in the brain and digestive system causing side effects. The major side effects of MAO inhibitors are high blood pressure, insomnia and weight gain.
The increasing patient pool of depression disorders worldwide and rising geriatric population that are highly prone to have mental health issues across the globe is expected to accelerate the market growth in the forecast period of 2022 to 2029. Furthermore, the factors such as the increasing government initiatives to spread awareness about the mental health among people will further carve the way for the growth of the market. The surge of development of novel drugs and techniques with fewer side-effects are also expected to boost the overall growth of the market within the above mentioned forecast period. However, the increase in patent expiration of antidepressant drugs is weakening the pipeline is projected to restraint the market growth rate. On the other hand, the poor efficacy and safety profiles of the drug also hampers the overall growth of the market.
In addition, the rise in the research and development activities in the market are likely to create various new opportunities that will impact this monoamine oxidase (MAO) inhibitor drugs market growth in the forecast period of 2022 to 2029.The low awareness regarding this drug and the side effects associated with MAO inhibitor is estimated to challenge the market’s growth.
This monoamine oxidase (MAO) inhibitor drugs market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the monoamine oxidase (MAO) inhibitor drugs market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Monoamine Oxidase (MAO) Inhibitor Drugs Market Scope and Market Size
Monoamine oxidase (MAO) inhibitor drugs market is segmented on the basis of types, drugs, disorder type, end users and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of types, the monoamine oxidase (MAO) inhibitor drugs market is segmented into MAO-A inhibitor and MAO-B inhibitor.
- On the basis of drugs, the monoamine oxidase (MAO) inhibitor drugs market is segmented into isocarboxazid, phenelzine, tranylcypromine and others.
- On the basis of disorder type, the monoamine oxidase (MAO) inhibitor drugs market is segmented into Parkinson’s disease, depression, anxiety and others.
- The monoamine oxidase (MAO) inhibitor drugs market is also segmented on the basis of end users into hospitals, homecare, specialty clinics and others.
- On the basis of distribution channel, the monoamine oxidase (MAO) inhibitor drugs market is segmented into hospital pharmacy, online pharmacy, retail pharmacy and others.
Monoamine Oxidase (MAO) Inhibitor Drugs Market Country Level Analysis
Monoamine oxidase (MAO) inhibitor drugs market is analyzed and market size information is provided by types, drugs, disorder type, end users and distribution channel as referenced above.
The countries covered in the monoamine oxidase (MAO) inhibitor drugs market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America leads the monoamine oxidase (MAO) inhibitor drugs market due to the high prevalence of an unhealthy lifestyle, and rising introduction of novel drugs in this region. Asia-Pacific region, on the other hand is expected to expand at a significant growth rate because of the increase in the vulnerable aging population of menopause women and increase in the demand of novel therapies.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Monoamine oxidase (MAO) inhibitor drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Monoamine Oxidase (MAO) Inhibitor Drugs Market Share Analysis
Monoamine oxidase (MAO) inhibitor drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to monoamine oxidase (MAO) inhibitor drugs market.
Some of the major players operating in the monoamine oxidase (MAO) inhibitor drugs market report are Takeda Pharmaceutical Company Limited, Mylan N.V., GlaxoSmithKline plc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Eli Lilly and Company, OrchidPharma Ltd., Validus Pharmaceuticals LLC, INDOCO REMEDIES LTD., Teikoku Pharma USA, Inc., H. Lundbeck A/S, Alliance Pharma PLC, Solvay, Cipla Inc, Allergan, SHIONOGI & Co., Ltd, BioSyent Inc., Glenmark Pharmaceuticals Limited, AstraZeneca, Johnson & Johnson Private Limited, Gedeon Richter., Luye Pharma Group, and Bristol-Myers Squibb Company among others.
SKU-